证券代码：688468 证券简称：科美诊断 公告编号：2024-030 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2024年5月20日（星期一）下午 15:00-17:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2024年5月17日（星期五）前通过科美诊断技术股份有限公司 （以下简称"公司"）邮箱ir@chemclin.com进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 公司于2024年4月30日在上海证券交易所网站（www.sse.com.cn）发布了《 2023年年度报告》和《2024年第一季度报告》，为便于广大投资者更全面深入地 了解公司2023年度以及2024年第一季度的经营成果、财务状况，公司计划于 2024年5月20日下午15:00-17:00参加由上海证券交易所主办的2023年度科创板制 药专场集体业绩 ...

中信证券股份有限公司 关于科美诊断技术股份有限公司 2023 年度持续督导工作现场检查报告 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 邵才捷、焦延延 （三）现场检查人员 邵才捷、王晨晨、杜雨林 （四）现场检查时间 2024 年 4 月 19 日、2024 年 4 月 26 日 （五）现场检查内容 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对科美诊断技术股份有限公司（以下简称"科美诊断""公司""上 市公司"）进行持续督导工作的保荐人，对 2023 年度（以下简称"本持续督导期 间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 现场检查人员对本持续督导期内发行人公司治理和内部控制情况、信息披露 情况、公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、 募集资金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面 进行了现场检查，具体检查内容详见本报告"二、本次现场检查主要事项及意见"。 （六）现场检查手段 1 本次 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/11/30，由董事会提议 | | --- | --- | | 回购方案实施期限 | 待第二届董事会第六次会议审议通过后 个月 12 | | 预计回购金额 | 3,000 万元~6,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | 累计已回购股数 | 651.4913 万股 | | 累计已回购股数占总股本比例 | 1.62% | | 累计已回购金额 | 万元 5,107.51 | | 实际回购价格区间 | 5.83 元/股~10.30 元/股 | 证券代码：688468 证券简称：科美诊断 公告编号：2024-029 科美诊断技术股份有限公司 一、 回购股份的基本情况 科美诊断技术股份有限公司（以下简称"公司"）于 2023 年 11 月 28 日召开第 二届董事会第六次会议，审议通过了《关于以集中竞价交易方式回购公司股份方 ...

Financial Performance - The company's operating revenue for 2023 was CNY 445,340,815.75, a decrease of 4.28% compared to CNY 465,270,072.25 in 2022[21]. - The net profit attributable to shareholders for 2023 was CNY 147,373,517.73, down 3.44% from CNY 152,625,664.32 in 2022[21]. - The net cash flow from operating activities decreased by 29.24% to CNY 173,053,196.46 in 2023 from CNY 244,559,713.21 in 2022[21]. - The total assets increased by 14.42% to CNY 1,820,562,566.47 at the end of 2023, compared to CNY 1,591,166,426.71 at the end of 2022[21]. - The company's net assets attributable to shareholders rose by 0.60% to CNY 1,388,801,768.59 at the end of 2023 from CNY 1,380,575,252.76 at the end of 2022[21]. - Basic earnings per share for 2023 were CNY 0.37, a decrease of 2.63% from CNY 0.38 in 2022[22]. - The company's comprehensive gross margin for the reporting period is 75.36%, remaining stable[96]. - The company achieved operating revenue of CNY 445.34 million, a year-on-year decrease of 4.28%[98]. - The net profit attributable to the parent company was CNY 147.37 million, down 3.44% compared to the previous year[98]. - Total assets reached CNY 1.82 billion, an increase of 14.42% from the beginning of the year[98]. - Total liabilities increased by 105.02% to CNY 431.76 million, resulting in a debt-to-asset ratio of 23.72%[98]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 18.78% in 2023 from 17.97% in 2022, reflecting a growth of 0.81 percentage points[22]. - The total R&D investment amounted to CNY 83.65 million, representing an increase of 0.04% compared to the previous year, with R&D expenses accounting for 18.78% of operating revenue[67]. - The company has developed a proprietary light-activated chemiluminescence technology platform, leading to the successful launch of the LiCA® series products[43]. - The company has established a well-established R&D system with a multidisciplinary team, enhancing its innovation capabilities and product development[54]. - The company has developed leading core technologies in infectious disease marker detection, including new-generation HIV antigen/antibody detection technology and HCV antigen-antibody combined detection technology[63]. - The company has developed over 40 high-quality biological raw materials to support its reagent development process, enhancing production capabilities by over 10 times for certain materials[69]. - The company has established a multi-tiered training program to enhance both organizational and individual capabilities[173]. - The number of R&D personnel has increased to 179, representing 24.49% of the total workforce, up from 22.64% in the previous period[73]. Product Development and Innovation - The company successfully obtained registration certificates for the LiCA®5000 and LiCA®5000 platform in vitro diagnostic reagents during the reporting period[33]. - The company is focusing on high-performance imported products to accelerate import substitution in the clinical chemistry immunoassay market, which is dominated by international manufacturers with a market share of 73%[34]. - The company has made significant progress in developing new products, including three registration certificates for hepatitis B quantitative projects, enhancing its leading position in blood-borne infectious disease detection[34]. - The company has developed 87 LiCA® series reagent products covering various clinical detection projects, achieving performance levels that meet or exceed international leading brands[56]. - The LiCA® series products demonstrated a sensitivity of 96.39% and a specificity of 99.95% in detecting HCV antibodies, surpassing the Abbott Architect i2000SR platform[76]. - The company is developing 20 additional reagents according to plan, enhancing its product line in the immunodiagnostic sector[69]. - The company has established a proprietary chemiluminescence technology platform, achieving international leading levels in key technologies such as nano-microsphere modification and chemiluminescence analysis[62]. Corporate Governance and Compliance - The company has established a comprehensive corporate governance structure involving the shareholders' meeting, board of directors, supervisory board, and management[195]. - The company emphasizes the importance of corporate governance, adhering to laws and regulations to maintain operational integrity and investor trust[138]. - The company held 1 shareholders' meeting in 2023, ensuring all procedures complied with relevant laws and regulations, with all proposals approved[142]. - The board of directors held 5 meetings in 2023, discussing key matters such as regular reports and governance system revisions, ensuring compliance with legal and regulatory requirements[138]. - The company has not faced any penalties from securities regulatory authorities in the past three years[161]. - The company has made adjustments to the audit committee's membership, electing a new member to enhance oversight[166]. Market Position and Strategy - The company aims to leverage its proprietary LiCA® technology to enhance its product offerings and achieve import substitution in the in vitro diagnostic market, which is currently dominated by foreign brands with a 75% market share[128]. - The company is committed to exploring new technologies and business models to build a comprehensive ecosystem in the in vitro diagnostic field[133]. - The company is focused on expanding its market presence and enhancing its product offerings through new technology development[153]. - The company maintains a strong brand presence in the domestic chemiluminescence infectious disease testing field, with a competitive product menu comparable to international brands[84]. - The company is advancing the construction of its Suzhou production base to meet changing market demands[33]. Risks and Challenges - The company faces risks of declining revenue due to national centralized procurement in the in vitro diagnostic industry and related hospital policy implementations[96]. - The risk of new product development and registration is significant, with a typical timeline of 3-5 years from project initiation to obtaining registration certificates[85]. - The company must manage environmental and safety risks associated with waste generated during production processes[93]. - The company is facing risks related to national healthcare reforms and product registration renewals, which could impact operational performance if not addressed[97]. Shareholder Returns - The proposed cash dividend distribution is 1.25 RMB per 10 shares, totaling approximately 49.32 million RMB, which accounts for 33.47% of the net profit attributable to shareholders for 2023[5]. - The company will not conduct capital reserve transfers to increase share capital or issue bonus shares[5]. - The cash dividend plan is subject to approval at the annual shareholders' meeting, ensuring compliance with corporate governance[176]. - The company has not proposed a capital reserve increase or stock dividend, focusing solely on cash dividends for shareholder returns[179].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 111,390,688.04, representing a year-on-year increase of 10.36%[5] - The net profit attributable to shareholders for the same period was CNY 38,392,507.40, reflecting a growth of 10.21% compared to the previous year[5] - Total operating revenue for Q1 2024 reached ¥111,390,688.04, an increase of 10.9% compared to ¥100,933,657.63 in Q1 2023[25] - Net profit for Q1 2024 was ¥38,392,507.40, representing a 10.5% increase from ¥34,836,760.84 in Q1 2023[26] - The total comprehensive income attributable to the parent company was CNY 38,392,507.40, compared to CNY 34,836,760.84 in Q1 2023, reflecting an increase of 7.9%[27] Cash Flow - The net cash flow from operating activities increased significantly by 106.70%, amounting to CNY 37,767,684.23, primarily due to increased sales collections[6] - In Q1 2024, the company reported a net cash flow from operating activities of CNY 37,767,684.23, a significant increase of 106.5% compared to CNY 18,271,622.63 in Q1 2023[29] - The net cash flow from investing activities was CNY 60,935,030.35, a turnaround from a negative cash flow of CNY -120,379,638.70 in Q1 2023[29] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 277,035,240.30, an increase from CNY 197,051,012.53 at the end of Q1 2023[29] - The company’s cash flow from financing activities showed a net outflow of CNY -23,274,506.27, contrasting with a net inflow of CNY 7,081,853.95 in Q1 2023[29] Research and Development - Research and development expenses totaled CNY 20,095,592.77, which is a decrease of 6.86% year-on-year, and accounted for 18.04% of operating revenue, down by 3.34 percentage points[6] - Research and development expenses for Q1 2024 amounted to ¥18,615,108.51, compared to ¥17,088,512.72 in Q1 2023, indicating a growth of 8.9%[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,044[9] - The largest shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management Partnership, held 26.93% of the shares, totaling 108,000,008 shares[10] - The top ten shareholders include significant entities such as Shanghai Peixi Investment Management Partnership and Ningbo Kebo Ao, with the largest shareholder holding 25,731,070 shares[13] - The company has not identified any other relationships or concerted actions among the remaining circulating shareholders[13] - The company has not engaged in any securities lending or borrowing activities among the top ten shareholders[14] Asset and Liability Overview - The total assets at the end of the reporting period were CNY 1,819,304,508.30, showing a slight decrease of 0.07% from the end of the previous year[6] - Current assets totaled ¥1,048,954,556.06, a decrease of 4.9% from ¥1,102,627,338.36 at the end of 2023[22] - Total liabilities amounted to ¥435,928,828.16, a slight increase from ¥431,760,797.88 in the previous period[23] - The company maintained a stable equity position with total equity at ¥1,383,375,680.14, slightly down from ¥1,388,801,768.59[23] Share Repurchase - As of March 31, 2024, the company has repurchased a total of 5,574,913 shares, accounting for 1.39% of the total share capital of 401,108,000 shares[15] - The total amount paid for the repurchased shares is RMB 44,650,529, with a maximum price of RMB 10.30 per share and a minimum price of RMB 5.83 per share[16] - The company plans to use between RMB 30 million and RMB 60 million for share repurchase, with a maximum repurchase price of RMB 16.68 per share[14] Other Financial Metrics - The weighted average return on equity increased by 0.28 percentage points to 2.77%[5] - The basic and diluted earnings per share for the quarter were both CNY 0.10, an increase of 11.11% year-on-year[5] - The company reported non-recurring gains of CNY 3,605,146.48 for the period, primarily from fair value changes of financial assets[8]

重要内容提示： 大股东持股的基本情况 证券代码：688468 证券简称：科美诊断 公告编号：2024-020 科美诊断技术股份有限公司 关于持股 5%以上股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 截至本公告日，科美诊断技术股份有限公司（以下简称"公司"）股东横琴君 联致康投资企业（有限合伙）（以下简称"横琴君联致康"）及其一致行动人 LOYAL CLASS LIMITED（以下简称"LOYAL CLASS"）分别持有公司股份16,620,486股、 12,960,031 股（合计持有 29,580,517 股），分别占公司总股本的 4.14%、3.23%（合 计占公司总股本的 7.37%）。 上述股份来源均为公司首次公开发行股票并上市前持有的股份，且已于 2022 年 4 月 11 日解除限售并上市流通。 减持计划的主要内容 因自身资金需求，横琴君联致康及 LOYAL CLASS 拟通过集中竞价交易、大 宗交易的方式减持公司股份，合计减持不超过 7,219,940 股，合计减持比例 ...

证券代码：688468 证券简称：科美诊断 公告编号：2024-019 二、 回购方案的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号 ——回购股份》等相关规定，公司在回购期间，应在每个月的前三个交易日内披露 截至上月末的回购进展情况。现将公司截至 2024 年 3 月 31 日的回购进展情况公告 如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/11/30，由公司董事会提议 | | --- | --- | | 回购方案实施期限 | 待第二届董事会第六次会议审议通过后 12 个月 | | 预计回购金额 | 万元 3,000 万元~6,000 | | 回购用途 | 用于员工持股计划或股权激励 | | 累计已回购股数 | 557.4913 万股 | | 累计已回购股数占总股本比例 | 1.39% | | 累计已回购金额 | 4,465.0529 万元 | | 实际回购价格区间 | 元/股~10.30 元/股 5.83 | 一、 回 ...

中信证券股份有限公司 关于科美诊断技术股份有限公司 首次公开发行部分限售股上市流通的核查意见 中信证券股份有限公司（以下简称"保荐机构"）担任科美诊断技术股份有 限公司（以下简称"科美诊断"、"发行人"或"公司"）首次公开发行股票并上 市持续督导期间的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证 券交易所科创板股票上市规则》等有关规定，对公司首次公开发行部分限售股上 市流通的事项进行了审慎核查，核查情况如下： 一、本次上市流通的限售股类型 中国证券监督管理委员会于 2021 年 2 月 24 日出具了《关于同意科美诊断技 术股份有限公司首次公开发行股票注册的批复》（证监许可[2021]550 号），同意 公司首次公开发行股票的注册申请。公司首次向社会公开发行人民币普通股 41,000,000 股，并于 2021 年 4 月 9 日在上海证券交易所科创板上市交易。公司 首次公开发行股票后，公司总股本为 401,000,000 股，其中有限售条件流通股 367,860,925 股，占公司总股本的 91.74%；无限售条件流通股 33,139,075 股，占 公司总股本的 8.26%。上述有限售条件流通股 ...

证券代码：688468 证券简称：科美诊断 公告编号：2024-018 科美诊断技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 126,000,006 股。 本次股票上市流通总数为 126,000,006 股。 本次股票上市流通日期为 2024 年 4 月 9 日。 一、本次上市流通的限售股类型 中国证券监督管理委员会于 2021 年 2 月 24 日出具了《关于同意科美诊断技 术股份有限公司首次公开发行股票注册的批复》（证监许可[2021]550 号），同意 公司首次公开发行股票的注册申请。公司首次向社会公开发行人民币普通股 41,000,000 股，并于 2021 年 4 月 9 日在上海证券交易所科创板上市交易。公司首 次公开发行股票后，公司总股本为 401,000,000 股，其中有限售条件流通股 367,860,925 股，占公司总股本的 91.74%；无限售条件流通股 33,139,075 股，占公 司总股本的 8 ...

证券代码：688468 证券简称：科美诊断 公告编号：2024-017 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科美诊断技术股份有限公司（以下简称"公司"或"科美诊断"）于2024年3月 26日召开第二届董事会第九次会议、第二届监事会第八次会议，审议通过了《 关于部分募投项目延期的议案》，同意公司2021年首次公开发行股票募集资金 投资项目（以下简称"募投项目"）"LiCA®试剂与配套仪器研发（实验室） 项目"及"LiCA®试剂与关键生物原料研发项目"的项目完成日期分别调整至 2024年11月、2025年4月。监事会发表了明确同意的意见，保荐机构中信证券股 份有限公司（以下简称"保荐机构"）出具了明确同意的核查意见。上述事项在 公司董事会审批权限范围内，无需提交公司股东大会审批。现将相关情况公告 如下： 一、募集资金基本情况 （一）实际募集资金金额基本情况 2021年2月24日，中国证券监督管理委员会作出《关于同意科美诊断技术股 份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕550号），同意 公司首次 ...